Our liquid biopsy solutions deliver precise circulating tumor DNA testing to support cancer research, therapy evaluation, and biomarker development.
Our liquid biopsy MRD solutions combine analytical precision with clinical expertise. The Vista platform enables highly sensitive MRD detection and circulating tumor DNA test applications, ensuring accurate therapy response monitoring and early relapse identification in research and clinical trials.
Highly sensitive circulating tumor DNA detection for minimal residual disease (MRD) across multiple cancer types, enabling three-stage patient monitoring:
Ideal for lymphomas and solid tumors. Learn more about our liquid biopsy lymphoma and solid tumor research applications.
Development of customized liquid biopsy diagnostics for specific research and clinical needs:
Applicable for pharmaceutical, biotech, and academic research projects.
Comprehensive support for all clinical study phases:
Applicable for Phase I–III studies and companion diagnostic programs.
Identification and validation of circulating tumor DNA biomarkers for translational and clinical research:
Enabling breakthroughs in drug development and personalized medicine.
Established Expertise: Clinically validated tests for B-cell lymphomas and Hodgkin lymphomas with proven prognostic significance.
Technically validated: CancerVista for solid tumors with cross-tumor gene panel. Target indications include lung, breast, colorectal, prostate, ovarian, pancreatic cancers, and glioblastoma.
The clinical value of MRD detection is well established in solid tumors, especially colorectal cancer3, breast cancer4 and lung cancer5.
Define research goals, study design, and technical requirements.
Adapt or create Vista assays for your specific study.
Conduct technical and clinical validation per regulatory standards.
Perform sample analysis, data evaluation, and provide ongoing project support.
LIQOMICS operates under strict quality assurance and international standards:
Quality assurance according to German regulations
International laboratory quality compliance
Secure and ethical data processing
All results undergo technical and medical validation
1 Schleifenbaum et al. Presentation at European Hematology Association (EHA) Annual Meeting 2024
2 Mattlener et al. Presentation at American Society of Hematology (ASH) Annual Meeting 2024
3 Jácome & Johnson. Minimal Residual Disease in Colorectal Cancer: Are We Finding the Needle in a Haystack? (2023)
4 Sabit, Attia & Mohamed et al. Beyond traditional biopsies: the emerging role of ctDNA and MRD on breast cancer diagnosis and treatment (2025)
5 Boukouris, Michaelidou & Joosse et al. A comprehensive overview of minimal residual disease in the management of early-stage and locally advanced non-small cell lung cancer (2025)
Contact us for a non-binding consultation regarding your liquid biopsy diagnostics and circulating tumor DNA detection requirements.
